Noxopharm commences SOF-SKN manufacturing ahead of planned clinical trial
Noxopharm Limited (ASX: NOX) has commenced manufacturing SOF-SKN for a clinical trial planned for later this year. The manufacturing process is expected to take several weeks, including quality control checks involving physical, chemical and biological tests.
The move follows the successful Phase I HERACLES trial as the company prepares for a potential clinical trial later this year. The manufacturing approach supports future efficiencies and low supply chain risks, reinforced by a favourable active ingredient stability profile that enables a strategic drug manufacture approach.
SOF-SKN’s localised pharmacokinetic profile, confirmed through preclinical studies showing a 3.5-day half-life in skin tissue and systemic absorption remaining below quantifiable levels, underpins the favourable stability characteristics that make the strategic manufacturing approach viable.
Taking place in a controlled environment, the process utilises a proven methodology. The manufactured product will also support preclinical investigations, including dose range-finding experiments, therapeutic models, and further characterisation of SOF-SKN’s stability profile.
When big ASX news breaks, our subscribers know first
What is cutaneous lupus erythematosus?
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disease where the body’s immune system mistakenly attacks healthy skin tissue, causing inflammation. The condition creates visible skin lesions and can significantly impact quality of life.
Currently, there is a lack of targeted treatments on the market for CLE patients.
Market opportunity and expansion potential
The global CLE market is worth more than US$3.3 billion and is expected to grow significantly over the coming years. Beyond dermatology, SOF-SKN could expand into additional autoimmune-related skin diseases, including psoriasis and dermatomyositis.
The broader Sofra technology platform may support future development opportunities across diseases associated with immune system dysregulation, including rheumatoid arthritis and diabetes. The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035.
| Market Segment | Current Value | Projected Value |
|---|---|---|
| Global CLE market | US$3.3 billion+ | Growing significantly |
| Autoimmune therapeutics | US$163.2 billion (2024) | US$219.6 billion (2035) |
The commercial pathway extends beyond the initial CLE indication. Platform optionality provides multiple shots on goal, with technology potentially applicable across a wide range of immune system-related diseases.
Near-term clinical pathway and pilot study plans
Dr Olivier Laczka, CEO
“Following the success of our Phase I HERACLES trial and the lack of targeted treatments on the market for people with cutaneous lupus erythematosus (CLE), we are preparing to be ready for any opportunity to test SOF-SKN in patients. Currently, we are actively investigating prospects for a pilot study in a local patient population, which would act as a valuable guide for a future Phase II trial. We will update shareholders in due course and are looking to progress this project as quickly as possible.”
The manufactured product will support preclinical work alongside clinical readiness. This includes dose range-finding experiments, therapeutic models, and further stability characterisation of SOF-SKN, which has been shown to be very good.
The dual-track approach maximises utility of the manufacturing investment, preparing the asset for clinical deployment while generating supporting preclinical data.
About the Sofra technology platform
The Sofra technology platform is based on short nucleic acid sequences known as oligonucleotides, which are the building blocks of DNA or RNA. These act on specific immune sensors to regulate inflammation at its source, either reducing or stimulating it to control disease.
Nature Immunology validation of the Sofra platform’s anti-inflammatory mechanism, published earlier this year with endorsement from Professor Arthur Krieg, provides the peer-reviewed scientific foundation from which SOF-SKN’s oligonucleotide approach to immune sensor regulation was advanced into clinical and manufacturing readiness.
Noxopharm operates two proprietary technology platforms:
- Sofra: Applications in inflammation, autoimmunity, mRNA drug enhancement, and oncology
- Chroma: Focused on oncology applications
The platform approach means SOF-SKN success could validate technology applicable across multiple indications, de-risking future pipeline development. Beyond dermatology, the underlying technology may support development opportunities in rheumatoid arthritis, lupus, diabetes and cancer.
What to watch for next
Investors should monitor these near-term milestones for visibility into execution progress and clinical pathway clarity:
- Completion of SOF-SKN manufacturing and quality control checks (expected to take several weeks)
- Update on pilot study investigation progress in local patient population
- Preclinical data from dose range-finding and therapeutic model experiments
These catalysts will provide insight into whether the company can translate manufacturing readiness into clinical trial initiation and data generation. The pilot study outcome, if secured, would be particularly material as it would guide the design and endpoints for a future Phase II trial.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving biotech announcements break.